Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases

Bevacizumab is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with brain metastases could be better-studied. This study examines a population of non-small cell lung cancer (NSCLC) patients with synchronous brain metastases to identify predictors of the decision t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascha, Mustafa S., Wang, Jacqueline Fang, Kumthekar, Priya, Sloan, Andrew E., Kruchko, Carol, Barnholtz-Sloan, Jill S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882803/
https://www.ncbi.nlm.nih.gov/pubmed/31780762
http://dx.doi.org/10.1038/s41598-019-54513-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882803/
https://www.ncbi.nlm.nih.gov/pubmed/31780762
http://dx.doi.org/10.1038/s41598-019-54513-3

Ejemplares similares